EVOLITO
22.9.2021 13:17:13 CEST | Business Wire | Press release
Evolito, a new company developing and manufacturing electric motors and power electronics for aerospace applications, launched publicly today as a privately-owned business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210922005519/en/
Evolito was spun out earlier this year by YASA (the world-leading pioneer of automotive axial-flux electric motors acquired by Mercedes-Benz in July 2021) to exclusively commercialise YASA’s next-generation electric motor technology and IP for the rapidly-growing aerospace market.
The business’s axial-flux motor technology has been proven in volume series production in the automotive industry and has even greater advantages in the aerospace market. As such, Evolito is uniquely positioned to drive forward the commercialisation and adoption of electric flight.
Evolito’s ultra high-performance, low-weight axial-flux motors and power electronics are smaller, lighter and more robust than any other competing technology, opening up a range of new opportunities for Electric Vertical Take-off and Landing (eVTOL), Fixed Wing and distributed electric propulsion applications such as Urban Air Mobility (UAM).
The unique segmented topology of the Evolito motor is inherently more robust than other electric motor approaches, making it ideally suited to the demands of the aerospace market where safety is paramount.
Cyrus Jilla, Partner and Board Director, Waypoint Capital said, “At Waypoint, one of our thematic interests is in energy transition and sustainability, including electrification. We look to invest in businesses with unique disruptive technology led by outstanding teams. Evolito is a perfect fit for us and we look forward to backing the team as they develop their game-changing electrification solutions for the aerospace market, making emissions-free flight a reality.”
Alexis Zervoglos, Senior Partner, OSE said, “The electrification of flight is one of the most exciting market opportunities of our time. Realising this potential will require innovative new technology and an ability to scale to meet the fast-emerging demand. OSE is delighted to be supporting Evolito on its mission to accelerate the adoption of electric flight.”
Gareth Morris, Managing Director, Evolito said, “Electrification in aerospace is some ten years behind that of the automotive industry, but the market potential is huge. Electric Vertical Take-off and Landing, Electric Helicopter, Fixed-Wing and Urban Air Mobility aircraft need high power density, low weight electric powertrains with inherently high safety factors - a combination of attributes that are unique to our axial-flux electric motor and power electronics. By leveraging YASA’s unique IP in the aerospace market, Evolito will fast-track the commercialisation of electric flight and transform mobility as we know it.”
EDITOR’S NOTES
Electric drive solutions for the Urban Air Mobility market are forecast to grow to USD $90 billion and 160,000 vehicles by 2050. Source: Roland Berger “The high-flying industry: Urban Air Mobility takes off” , Nov, 2020.
Evolito http://www.evolito.co.uk/
Evolito is making all-electric flight a commercial reality with world-leading direct-drive electric propulsion solutions. Spun out of YASA in 2021, Evolito leverages technology proven by OEMs in the EV industry. Evolito’s axial-flux electric motors and power electronics offer the highest power and torque densities in class – mission critical in eVTOL, Urban Air Mobility and fixed-wing applications – and is inherently more robust than competing technologies. The privately-held company is based in Oxford. Evolito’s investors include Waypoint Capital and Oxford Science Enterprises (OSE).
YASA http://www.yasa.com/
YASA, part of Mercedes-Benz AG, is a pioneer in next-generation electric drive technology. YASA’s unique axial-flux electric motor technology offers the greatest efficiencies and highest power densities in class for the smallest size and weight. YASA is based in Oxford and Welshpool, UK.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005519/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom